Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the feasibility of delivering symptom-triggered alcohol withdrawal management by telemedicine and determine whether this intervention is satisfactory to patients.


Clinical Trial Description

This single-arm pilot feasibility study will recruit actively drinking participants with a history of alcohol withdrawal in order to provide remotely monitored symptom-triggered alcohol withdrawal treatment using telemedicine. Participants will initially complete a screening and eligibility visit. If eligible, participants will then be scheduled for 3-day remote withdrawal management (which can be extended by 1-2 days if medically indicated). During remote withdrawal management, participants will receive symptom-triggered diazepam treatment using a modified version of the Clinical Institute Withdrawal Assessment for Alcohol Scale, revised (CIWA-Ar). Within one week following termination of withdrawal treatment, participants will be scheduled for a remote follow up visit in which they will complete patient satisfaction questionnaires and will be offered weekly counselling sessions and anticraving medication to prevent relapse to alcohol use. Approximately 30 days following treatment initiation, relapse to alcohol use will be assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04858490
Study type Interventional
Source Centre for Addiction and Mental Health
Contact Rosaria Furlano, PhD
Phone 416-535-8501
Email [email protected]
Status Recruiting
Phase N/A
Start date April 2021
Completion date September 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03916939 - Osteopathic Treatment to Alcohol Withdrawal Syndrome N/A
Recruiting NCT04876443 - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Not yet recruiting NCT03586089 - Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome N/A
Completed NCT02349477 - Gabapentin for Alcohol Relapse Prevention Phase 2
Terminated NCT01937364 - Preventing Alcohol Withdrawal With Oral Baclofen Phase 2
Completed NCT00523185 - A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal N/A
Completed NCT01573052 - Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Phase 4
Recruiting NCT03737864 - NCARE, Transition to Recovery N/A
Recruiting NCT03878225 - Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans? N/A
Not yet recruiting NCT04793685 - Prazosin for Alcohol Use Disorder Phase 1/Phase 2
Not yet recruiting NCT04232800 - Riboflavin for Glutamate Reduction in Alcohol Withdrawal Phase 2
Recruiting NCT04156464 - Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit Phase 4
Completed NCT02251912 - Oxytocin Treatment of Alcohol Dependence Phase 2
Completed NCT02202148 - Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal N/A
Completed NCT01212185 - Oxytocin Treatment of Alcohol Withdrawal Phase 1
Not yet recruiting NCT04159909 - Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal N/A
Not yet recruiting NCT04205682 - Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal Early Phase 1
Completed NCT02275611 - Oxytocin Treatment of Alcohol Dependence Phase 2
Completed NCT01184417 - Phenobarbital for Acute Alcohol Withdrawal N/A
Completed NCT02835365 - Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France